Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium Tuberculosis that Target Leucyl-tRNA Synthetase.
Palencia, A., Li, X., Bu, W., Choi, W., Ding, C.Z., Easom, E.E., Feng, L., Hernandez, V., Houston, P., Liu, L., Meewan, M., Mohan, M., Rock, F.L., Sexton, H., Zhang, S., Zhou, Y., Wan, B., Wang, Y., Franzblau, S.G., Woolhiser, L., Gruppo, V., Lenaerts, A.J., O'Malley, T., Parish, T., Cooper, C.B., Waters, M.G., Ma, Z., Ioerger, T.R., Sacchettini, J.C., Rullas, J., Angulo-Barturen, I., Perez-Herran, E., Mendoza, A., Barros, D., Cusack, S., Plattner, J.J., Alley, M.R.K.(2016) Antimicrob Agents Chemother 60: 6271
- PubMed: 27503647 
- DOI: 10.1128/AAC.01339-16
- Primary Citation of Related Structures:  
5AGR, 5AGS, 5AGT - PubMed Abstract: 
The recent development and spread of extensively drug-resistant and totally drug-resistant resistant (TDR) strains of Mycobacterium tuberculosis highlight the need for new antitubercular drugs. Protein synthesis inhibitors have played an important role in the treatment of tuberculosis (TB) starting with the inclusion of streptomycin in the first combination therapies ...